3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Temozolomide
45
Radiotherapy
17
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Bevacizumab
12
pembrolizumab
11
Lomustine
9
Radiation
8
fludarabine
7
Cyclophosphamide
7
atezolizumab
4
Biopsy
4
olaparib
3
Transurethral Resection of Bladder
3
Surgical Procedures, Operative
3
Nivolumab
3
Leukapheresis
3
D2C7-(scdsFv)-PE38KDEL
3
Blood Specimen Collection
3
Aminolevulinic Acid
3
regorafenib
2
fluciclovine F-18
2
contrast agent BR1
2
antisecretory factor
2
abemaciclib
2
Restraint, Physical
2
Re-Irradiation
2
Radiation Dose Hypofractionation
2
Palliative Care
2
Oncolytic Virotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Glioblastoma
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled
NCT06640582
2024-11-05
BAH2472
Essen Biotech
Phase 1/2
Recruiting
85 enrolled